title: Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme.
abstract: Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan-Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6-16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (P < 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma.
authors.affiliation: Department of Neurosurgery, Bundeswehrkrankenhaus Berlin, Scharnhorststr. 13, 10115, Berlin, Germany. maier-hauff@cbn-berlin.de
authors.forename: Klaus
authors.initials: K
authors.lastname: Maier-Hauff
authors.forename: Frank
authors.initials: F
authors.lastname: Ulrich
authors.forename: Dirk
authors.initials: D
authors.lastname: Nestler
authors.forename: Hendrik
authors.initials: H
authors.lastname: Niehoff
authors.forename: Peter
authors.initials: P
authors.lastname: Wust
authors.forename: Burghard
authors.initials: B
authors.lastname: Thiesen
authors.forename: Helmut
authors.initials: H
authors.lastname: Orawa
authors.forename: Volker
authors.initials: V
authors.lastname: Budach
authors.forename: Andreas
authors.initials: A
authors.lastname: Jordan
mesh_terms: D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005290:Ferric Compounds / Q000008:administration & dosage*; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008280:Magnetics; D008875:Middle Aged; D053758:Nanoparticles / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D038361:Neuronavigation
chemical_list: D005290:Ferric Compounds; C000499:ferric oxide